Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xoma ( (XOMA) ) has shared an update.
XOMA Royalty Corporation announced a leadership transition in its finance organization, effective January 12, 2026, with the appointment of 41-year-old industry veteran Jeffrey Trigilio as Chief Financial Officer, succeeding long-serving finance chief Thomas Burns, who stepped down on the same date and formally ended his employment on January 15, 2026. Trigilio, who brings senior financial and operational experience from Obsidian Therapeutics, Cullinan Therapeutics, and other biotech roles and investment banking, has entered into an employment agreement that aligns his compensation and performance-based equity incentives with XOMA Royalty’s stock performance and long-term growth, while Burns departs with severance, accelerated vesting of certain performance stock units, and a short-term consulting role to support a smooth transition; the move underscores XOMA Royalty’s effort to reinforce its financial leadership as it pursues further expansion of its royalty portfolio in the biotech sector.
The most recent analyst rating on (XOMA) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Xoma stock, see the XOMA Stock Forecast page.
Spark’s Take on XOMA Stock
According to Spark, TipRanks’ AI Analyst, XOMA is a Neutral.
The score is driven primarily by mixed financial quality: strong margins and improved profitability are offset by high leverage and weak cash-flow growth/operating cash conversion. Technical signals are also mixed (negative MACD with neutral RSI and a split across moving averages). Valuation is a headwind given the high P/E and no stated dividend yield, while recent corporate updates are modestly supportive.
To see Spark’s full report on XOMA stock, click here.
More about Xoma
XOMA Royalty Corporation is a biotechnology royalty aggregator focused on acquiring potential future economics—milestones and royalty rights—linked to pre-commercial and commercial therapeutic candidates licensed to pharmaceutical and biotech companies. By purchasing these future economic interests, XOMA Royalty provides non-dilutive, non-recourse funding to sellers, supporting drug development or general corporate needs, and has built an extensive and growing portfolio of commercial and investigational assets within the biotech royalty segment of the healthcare ecosystem.
Average Trading Volume: 208,623
Technical Sentiment Signal: Buy
Current Market Cap: $363.6M
See more insights into XOMA stock on TipRanks’ Stock Analysis page.